Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (12693)	7/18/2003 10:49:22 AM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

Jim, CG, There's clear value here. We need a couple of things to change here in order to start seeing some of it. One I think is the style of management which overall may be too defensive. Another might be that regulatory bodies have a more equitable relationship with their own guidelines. Pennsaid in Canada is doing well although I don't know what kind of numbers that translates into - but I do believe they will form a solid base given some time. The strong patent in europe solidifies the belief in the value of OXO; but, the inability to get the phase III out of its purgatory of data gathering diminishes that value to DMX now. The picking away at cash tidbits without correlation to the reaction to the stockprice over years was a serious miscalculation caused I assume by the expectation that regulatory bodies can be counted on to follow through once they have all the information they asked for. Whatever side of this arugment we are on, its at least unacceptable that no answer of any kind comes. Thank god we had pull in Canada. These situations will be resolved and the stockprice has been pounded until it is. With what I expect are solid growth shipment numbers in Canada it will likely be easier to get the next infusion of capital and once the WF10 phase III's are in house I'm quite confident those results will show DMX is sitting on some serious value. This however is the only biotech in my lifetime. I simply will not put my money before regulatory bodies again. That Pennsaid and its clones become the mainstay of the treatment of OA symptoms I have zero doubt. That DMX made mistakes in going through these processes I also have no doubt. Its also fair to say that this particular drug is different and that all potential drugs sound good at some stage. However the priorities of individual countries and the influences surrounding those create a level of dysfunction that I am unwilling to participate in again. I'm satisfied that the risks here have diminished even as some might believe they are at their height. That does all predicate on the Canadian sales and these numbers will become evident soon enough. The buzz and activity (sales) for Pennsaid are doing well now that its finally in an arthritis market. Lets hope the Italians find the same thing. For a regulatory body to take almost a year without asking for anything new and understanding that the application is complete - either a yes or a no - is in my opinion unrelated to the merits of the application and is a clear indication of the state of its own dysfunction. Wolf